JP2011500851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500851A5 JP2011500851A5 JP2010531299A JP2010531299A JP2011500851A5 JP 2011500851 A5 JP2011500851 A5 JP 2011500851A5 JP 2010531299 A JP2010531299 A JP 2010531299A JP 2010531299 A JP2010531299 A JP 2010531299A JP 2011500851 A5 JP2011500851 A5 JP 2011500851A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patient
- active agent
- dry powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 239000013543 active substance Substances 0.000 claims 7
- 239000005556 hormone Substances 0.000 claims 6
- 229940088597 hormone Drugs 0.000 claims 6
- 239000000843 powder Substances 0.000 claims 6
- 239000002552 dosage form Substances 0.000 claims 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 230000002124 endocrine Effects 0.000 claims 4
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 claims 4
- 230000002685 pulmonary effect Effects 0.000 claims 4
- 125000000349 (Z)-3-carboxyprop-2-enoyl group Chemical group O=C([*])/C([H])=C([H])\C(O[H])=O 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 230000015556 catabolic process Effects 0.000 claims 2
- 238000006731 degradation reaction Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- -1 glutaryl Chemical group 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 2
- QIQCZROILFZKAT-UHFFFAOYSA-N tetracarbon dioxide Chemical group O=C=C=C=C=O QIQCZROILFZKAT-UHFFFAOYSA-N 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 230000017531 blood circulation Effects 0.000 claims 1
- 229940112141 dry powder inhaler Drugs 0.000 claims 1
- 210000005095 gastrointestinal system Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98236807P | 2007-10-24 | 2007-10-24 | |
| US60/982,368 | 2007-10-24 | ||
| US98562007P | 2007-11-05 | 2007-11-05 | |
| US60/985,620 | 2007-11-05 | ||
| US2227408P | 2008-01-18 | 2008-01-18 | |
| US61/022,274 | 2008-01-18 | ||
| US3374008P | 2008-03-04 | 2008-03-04 | |
| US61/033,740 | 2008-03-04 | ||
| US5212708P | 2008-05-09 | 2008-05-09 | |
| US61/052,127 | 2008-05-09 | ||
| US9482308P | 2008-09-05 | 2008-09-05 | |
| US61/094,823 | 2008-09-05 | ||
| PCT/US2008/081221 WO2009055742A2 (en) | 2007-10-24 | 2008-10-24 | Delivery of active agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015145109A Division JP2015227357A (ja) | 2007-10-24 | 2015-07-22 | 活性薬剤の送達方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500851A JP2011500851A (ja) | 2011-01-06 |
| JP2011500851A5 true JP2011500851A5 (enExample) | 2011-12-08 |
| JP5813323B2 JP5813323B2 (ja) | 2015-11-17 |
Family
ID=40545981
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010531299A Active JP5813323B2 (ja) | 2007-10-24 | 2008-10-24 | 活性薬剤の送達方法 |
| JP2015145109A Pending JP2015227357A (ja) | 2007-10-24 | 2015-07-22 | 活性薬剤の送達方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015145109A Pending JP2015227357A (ja) | 2007-10-24 | 2015-07-22 | 活性薬剤の送達方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US8372804B2 (enExample) |
| EP (1) | EP2214647A2 (enExample) |
| JP (2) | JP5813323B2 (enExample) |
| KR (2) | KR20100090692A (enExample) |
| CN (1) | CN101969928B (enExample) |
| AU (1) | AU2008316636B2 (enExample) |
| BR (1) | BRPI0818874A2 (enExample) |
| CA (1) | CA2703234C (enExample) |
| MX (1) | MX2010004508A (enExample) |
| RU (2) | RU2467741C2 (enExample) |
| WO (1) | WO2009055742A2 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2395096T3 (es) | 1999-06-29 | 2013-02-08 | Mannkind Corporation | Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| JP4681231B2 (ja) | 2002-03-20 | 2011-05-11 | マンカインド コーポレイション | 吸入装置 |
| US8921311B2 (en) | 2003-08-01 | 2014-12-30 | Mannkind Corporation | Method for treating hyperglycemia |
| ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| MX373000B (es) | 2005-09-14 | 2020-05-21 | Mannkind Corp | Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas. |
| CN104383546B (zh) | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| KR20100090692A (ko) * | 2007-10-24 | 2010-08-16 | 맨카인드 코포레이션 | 활성제의 전달 |
| KR101736502B1 (ko) | 2007-10-24 | 2017-05-16 | 맨카인드 코포레이션 | Ｇｌｐ-1에 의한 유해 효과의 예방 방법 |
| US8785396B2 (en) | 2007-10-24 | 2014-07-22 | Mannkind Corporation | Method and composition for treating migraines |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| MY155524A (en) | 2008-06-13 | 2015-10-30 | Mannkind Corp | A dry powder inhaler and system for drug delivery |
| EP2609954B1 (en) | 2008-06-20 | 2021-12-29 | MannKind Corporation | An interactive apparatus for real-time profiling of inhalation efforts |
| TWI494123B (zh) * | 2008-08-11 | 2015-08-01 | Mannkind Corp | 超快起作用胰島素之用途 |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US9750903B2 (en) | 2008-12-30 | 2017-09-05 | Gearbox, Llc | Method for administering an inhalable compound |
| US20100169260A1 (en) * | 2008-12-30 | 2010-07-01 | Searete Llc | Methods and systems for presenting an inhalation experience |
| SI2379100T1 (sl) * | 2009-01-08 | 2015-02-27 | Mannkind Corporation | Zdravljenje hiperglikemije z GLP-1 |
| US8538707B2 (en) | 2009-03-11 | 2013-09-17 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
| SG10201403147SA (en) * | 2009-06-12 | 2014-10-30 | Mannkind Corp | Diketopiperazine microparticles with defined isomer contents |
| AU2010259943C1 (en) * | 2009-06-12 | 2016-03-03 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| RU2673525C2 (ru) | 2009-11-02 | 2018-11-27 | Мэннкайнд Корпорэйшн | Способ для производства микрочастиц соединения |
| AU2015201885B2 (en) * | 2009-11-02 | 2017-04-20 | Mannkind Corporation | Apparatus and method for cryogranulating a pharmaceutical composition |
| KR101822208B1 (ko) | 2009-11-02 | 2018-01-25 | 맨카인드 코포레이션 | 약학적 조성물을 극저온 과립화하는 장치 및 방법 |
| JP5784622B2 (ja) | 2009-11-03 | 2015-09-24 | マンカインド コーポレ−ション | 吸入活動をシミュレートするための装置及び方法 |
| US8790704B2 (en) * | 2010-06-10 | 2014-07-29 | Monosol Rx, Llc | Combination peptide-nanoparticles and delivery systems incorporating same |
| RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
| AU2015249177B2 (en) * | 2010-11-09 | 2017-08-03 | Mannkind Corporation | Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines |
| MX376862B (es) * | 2010-11-09 | 2025-03-07 | Mannkind Corp | Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas. |
| MX353285B (es) | 2011-04-01 | 2018-01-05 | Mannkind Corp | Paquete de blister para cartuchos farmaceuticos. |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| HK1201475A1 (en) | 2011-10-24 | 2015-09-04 | Mannkind Corporation | Methods and compositions for treating pain |
| AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
| EP2890391A4 (en) * | 2012-08-29 | 2016-03-09 | Mannkind Corp | METHOD AND COMPOSITION FOR TREATING HYPERGLYCEMIA |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| BR112015023168B1 (pt) * | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
| BR122019026637B1 (pt) * | 2013-07-18 | 2023-09-26 | Mannkind Corporation | Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco |
| CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| IL260823B2 (en) * | 2016-01-29 | 2024-08-01 | Mannkind Corp | Dry powder inhaler |
| TW202541834A (zh) * | 2024-04-16 | 2025-11-01 | 南韓商韓美藥品股份有限公司 | 吸入用組成物 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4356167A (en) * | 1978-01-27 | 1982-10-26 | Sandoz, Inc. | Liposome drug delivery systems |
| US4483922A (en) * | 1982-05-14 | 1984-11-20 | Amf Inc. | Inactivation of enzymes |
| US4581020A (en) * | 1983-07-18 | 1986-04-08 | Trimedyne, Inc. | Medication delivery device and system for percutaneous administration of medication |
| US4849227A (en) | 1986-03-21 | 1989-07-18 | Eurasiam Laboratories, Inc. | Pharmaceutical compositions |
| US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
| US5693338A (en) | 1994-09-29 | 1997-12-02 | Emisphere Technologies, Inc. | Diketopiperazine-based delivery systems |
| US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
| DK36392D0 (da) | 1992-03-19 | 1992-03-19 | Novo Nordisk As | Anvendelse af kemisk forbindelse |
| US6024090A (en) | 1993-01-29 | 2000-02-15 | Aradigm Corporation | Method of treating a diabetic patient by aerosolized administration of insulin lispro |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5574008A (en) | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
| AU691361B2 (en) | 1994-12-01 | 1998-05-14 | Toyama Chemical Co. Ltd. | Novel 2,3-diketopiperazine derivative or salt thereof |
| US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
| US6277819B1 (en) | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| US6006753A (en) | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| EP0941114B1 (en) | 1996-11-12 | 2005-02-23 | Novo Nordisk A/S | Use of glp-1 peptides |
| AU1617399A (en) | 1997-12-05 | 1999-06-28 | Eli Lilly And Company | Glp-1 formulations |
| US6380357B2 (en) | 1997-12-16 | 2002-04-30 | Eli Lilly And Company | Glucagon-like peptide-1 crystals |
| CA2228182C (en) * | 1998-01-26 | 2007-03-20 | George Volgyesi | Breath-powered mist inhaler |
| SE9802080D0 (sv) | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
| US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
| DK1165050T3 (da) | 1999-04-05 | 2006-05-01 | Mannkind Corp | Fremgangsmåde til dannelse af fint pulver |
| SI1133312T1 (sl) | 1999-06-21 | 2008-02-29 | Lilly Co Eli | Uporaba tiazolidindionov v kombinaciji z glukagonu podobnim peptidom-1 in njegovimi agonisti za zdravljenje sladkorne bolezni, neodvisne od inzulina |
| ES2395096T3 (es) | 1999-06-29 | 2013-02-08 | Mannkind Corporation | Purificación y estabilización de agentes farmacéuticos a base de péptidos y proteínas |
| US7305986B1 (en) | 1999-07-23 | 2007-12-11 | Mannkind Corporation | Unit dose capsules for use in a dry powder inhaler |
| US7464706B2 (en) | 1999-07-23 | 2008-12-16 | Mannkind Corporation | Unit dose cartridge and dry powder inhaler |
| US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
| US6608038B2 (en) | 2000-03-15 | 2003-08-19 | Novartis Ag | Methods and compositions for treatment of diabetes and related conditions via gene therapy |
| DE60137876D1 (de) | 2000-06-16 | 2009-04-16 | Lilly Co Eli | Analoge des Glucagon-ähnlichen Peptids-1 |
| JP5048201B2 (ja) | 2000-08-04 | 2012-10-17 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | ジケトピペラジン類の使用方法とジケトピペラジン類を含む組成物 |
| AU2002239384B2 (en) * | 2000-12-13 | 2007-01-11 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| US7232897B2 (en) | 2001-04-24 | 2007-06-19 | Harvard University, President And Fellows Of Harvard College | Compositions and methods for modulating NH2-terminal Jun Kinase activity |
| JP2005506956A (ja) | 2001-06-01 | 2005-03-10 | イーライ・リリー・アンド・カンパニー | 長時間作用性ｇｌｐ−１製剤 |
| AU2002322403A1 (en) | 2001-08-23 | 2003-03-10 | Eli Lilly And Company | Glucagon-like peptide-1 analogs |
| WO2003020201A2 (en) | 2001-08-28 | 2003-03-13 | Eli Lilly And Company | Pre-mixes of glp-1 and basal insulin |
| EP1448222A4 (en) | 2001-10-19 | 2006-05-17 | Lilly Co Eli | BIPHASIC MIXTURES OF GLP-1 AND INSULIN |
| SE524990C2 (sv) * | 2002-04-12 | 2004-11-09 | Microdrug Ag | Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver |
| US20040038865A1 (en) | 2002-08-01 | 2004-02-26 | Mannkind Corporation | Cell transport compositions and uses thereof |
| US11304992B2 (en) * | 2002-08-01 | 2022-04-19 | Mannkind Corporation | Inhalable dry powder pharmaceutical composition |
| US20080260838A1 (en) * | 2003-08-01 | 2008-10-23 | Mannkind Corporation | Glucagon-like peptide 1 (glp-1) pharmaceutical formulations |
| EP1545457A4 (en) * | 2002-08-01 | 2009-07-01 | Mannkind Corp | CELL TRANSPORT COMPOSITIONS AND USES |
| US20040121964A1 (en) | 2002-09-19 | 2004-06-24 | Madar David J. | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) |
| NZ541365A (en) * | 2002-12-27 | 2009-09-25 | Diobex Inc | Compositions and methods for the prevention and control of insulin-induced hypoglycemia |
| CN102210852B (zh) * | 2003-05-15 | 2016-10-19 | 安皮奥制药股份有限公司 | T-细胞介导的疾病的治疗 |
| US20070027063A1 (en) * | 2004-01-12 | 2007-02-01 | Mannkind Corporation | Method of preserving the function of insulin-producing cells |
| ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
| BRPI0514410A (pt) | 2004-08-23 | 2008-06-10 | Mannkind Corp | fornecimento pulmonar de inibidores de fosfodiesterase do tipo 5 |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| DE102005033398A1 (de) * | 2004-11-10 | 2006-05-11 | Alfred Von Schuckmann | Inhalier-Gerät |
| SE0402976L (sv) | 2004-12-03 | 2006-06-04 | Mederio Ag | Medicinsk produkt |
| WO2007030706A1 (en) | 2005-09-08 | 2007-03-15 | New England Medical Center Hospitals, Inc. | Fragments of the glucagon-like peptide-i and uses thereof |
| MX373000B (es) * | 2005-09-14 | 2020-05-21 | Mannkind Corp | Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas. |
| US8039432B2 (en) * | 2005-11-09 | 2011-10-18 | Conjuchem, Llc | Method of treatment of diabetes and/or obesity with reduced nausea side effect |
| CN104383546B (zh) * | 2006-02-22 | 2021-03-02 | 曼金德公司 | 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法 |
| EP2471810A1 (en) * | 2006-02-22 | 2012-07-04 | Merck Sharp & Dohme Corporation | Oxyntomodulin derivatives |
| RU2409349C2 (ru) | 2006-04-14 | 2011-01-20 | Маннкайнд Корпорейшн | Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1) |
| RU2010102865A (ru) * | 2007-07-24 | 2011-08-27 | НексБио, Инк. (US) | Технология изготовления микрочастиц |
| KR20100090692A (ko) * | 2007-10-24 | 2010-08-16 | 맨카인드 코포레이션 | 활성제의 전달 |
| EP2060268A1 (en) | 2007-11-15 | 2009-05-20 | Novo Nordisk A/S | Pharmaceutical compositions for pulmonary or nasal delivery of peptides |
| EP2282763B1 (en) * | 2008-04-07 | 2013-12-11 | National Institute Of Immunology | Process for preparing supramolecular calcitonin assemblies (SCA) |
-
2008
- 2008-10-24 KR KR1020107011092A patent/KR20100090692A/ko not_active Ceased
- 2008-10-24 US US12/258,341 patent/US8372804B2/en active Active
- 2008-10-24 BR BRPI0818874 patent/BRPI0818874A2/pt not_active IP Right Cessation
- 2008-10-24 RU RU2010120672/15A patent/RU2467741C2/ru active
- 2008-10-24 WO PCT/US2008/081221 patent/WO2009055742A2/en not_active Ceased
- 2008-10-24 EP EP08840828A patent/EP2214647A2/en not_active Ceased
- 2008-10-24 JP JP2010531299A patent/JP5813323B2/ja active Active
- 2008-10-24 KR KR1020137027813A patent/KR20130123470A/ko not_active Ceased
- 2008-10-24 CN CN200880122681.1A patent/CN101969928B/zh active Active
- 2008-10-24 MX MX2010004508A patent/MX2010004508A/es active IP Right Grant
- 2008-10-24 AU AU2008316636A patent/AU2008316636B2/en active Active
- 2008-10-24 CA CA2703234A patent/CA2703234C/en active Active
-
2012
- 2012-08-23 RU RU2012136221/15A patent/RU2012136221A/ru not_active Application Discontinuation
-
2013
- 2013-01-09 US US13/737,823 patent/US20130118491A1/en not_active Abandoned
-
2015
- 2015-07-22 JP JP2015145109A patent/JP2015227357A/ja active Pending
-
2019
- 2019-02-04 US US16/267,231 patent/US20190167580A1/en not_active Abandoned
-
2020
- 2020-01-13 US US16/741,260 patent/US20200146981A1/en not_active Abandoned
-
2022
- 2022-07-14 US US17/864,828 patent/US20220362147A1/en active Pending
-
2024
- 2024-02-06 US US18/434,301 patent/US20240197627A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012136221A (ru) | Доставка активных веществ | |
| US10398673B2 (en) | Mast cell stabilizers treatment for systemic disorders | |
| JP2011500850A5 (enExample) | ||
| EP3536368B1 (en) | Dry powder inhaler comprising a serotonin receptor agonist and a diketopiperazine for treating migraines | |
| ES2775498T5 (es) | Formulación en polvo nasal para el tratamiento de la hipoglucemia | |
| JP2004522714A5 (enExample) | ||
| JP2007520506A5 (enExample) | ||
| ES2922551T3 (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| JP2013518124A5 (enExample) | ||
| JP2022535127A5 (enExample) | ||
| JP2020536121A5 (enExample) | ||
| JP2023524064A (ja) | ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法 | |
| JP2012532852A (ja) | ２型糖尿病における食後高血糖の経頬粘膜治療の方法、および当該治療に用いられる医薬組成物 | |
| JP7369523B2 (ja) | 中等度～重度のインフルエンザの処置 | |
| JP5117230B2 (ja) | ２型糖尿病治療用の併用医薬 | |
| Siekmeier et al. | Aerosolized GLP-1 for treatment of diabetes mellitus and irritable bowel syndrome | |
| CN1297272C (zh) | 马来酸氯苯那敏的新用途 | |
| Imenshahidi et al. | Pulmonary delivery of insulin by dry powder inhaler formulations | |
| TW202611066A (zh) | Glp-1類似物的醫藥用途 | |
| Roe et al. | Doctor, stop needling me: an update on alternative routes of insulin administration | |
| JP2007091641A (ja) | ２型糖尿病治療用の併用医薬 |